Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landogrozumab in Older Patients Undergoing Elective Total Hip Arthroplasty
NCT01369511Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2011
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of landogrozumab in muscle atrophy, sponsored by Eli Lilly and Company. Started Jul 2011; status: completed.
02
Drugs
landogrozumab
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on NCT01369511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01369511.